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Abstract
Globally, non-steroidal anti-inflammatory drugs
(NSAIDs) are highly used to treat pain. With the rise of
the COVID-19 pandemic, the safety of NSAIDs use has
been called into question. These concerns are worthy of
review. At present, there is no compelling data showing
that NSAIDs worsen the severity of COVID-19 symptoms
or increase one’s likelihood of contracting the illness.
For patients in pain and without symptoms that could
potentially be attributed to COVID-19 (cough, fevers/
chills, lethargy, myalgias, anosmia and so on), NSAIDs
should continue to remain a viable option to provide
analgesia to patients in need.

Introduction

Globally, non-
steroidal anti-
inflammatory drugs
(NSAIDs) are the most commonly used medications for the treatment of acute and chronic pain.
With appropriate patient selection and dosing,
these medications have served as a cornerstone of
the pharmacologic toolbox to treat pain since the
1800s.1 While NSAIDs can provide significant analgesia to patients in pain, this class of medications
carries risks including cardiovascular dysfunction,
bleeding, gastrointestinal upset and kidney injury.2
With the rise of the current coronavirus disease
2019 (COVID-19) global pandemic caused by the
spread of the severe acute respiratory syndrome
coronavirus 2 (SARS-
CoV-2), questions have
arisen regarding the safety of NSAIDs during this
period of uncertainty on how to best respond to
this novel disease. An assessment of the current
sources of concern surrounding NSAID use during
the pandemic can offer insight on their risk–benefit
profile for the treatment of pain at the present time.

Discussion
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The concern regarding NSAID use during the
pandemic was first published by three European
physicians and scientists in a letter to the editor
of the journal The Lancet Respiratory Medicine on 11 March 2020.3 While these authors
wrote primarily about hypertension and diabetes
mellitus as risk factors for contracting COVID19, they briefly commented that ibuprofen could
increase levels of cellularly expressed ACE2. This
is potentially concerning as SARS-CoV-2 infects
cells by binding to ACE2, which is commonly
expressed in tissues of the cardiovascular, gastrointestinal and renal systems.4 However, some
concerns raised in this letter are observational and
have yet to be proven. Furthermore, the authors
of this letter do not cite a source for their assertion that ibuprofen can increase levels of ACE2.
During our literature search on PubMed for this

article, we could not identify research to support
this. The uncertainty surrounding the origin
of this claim was also examined in an article in
Chemical & Engineering News, a trade magazine
published by the American Chemical Society.5
They report that the authors of the letter in The
Lancet did not offer specific clarification when
asked for evidence showing that ibuprofen actually increases ACE2 expression.
More widespread attention regarding NSAID use
was garnered by a tweet from the Health Minister
of France on 14 March 2020. Oliver Veran advised
against using medications like ibuprofen and
cortisone and recommended the use of acetaminophen (paracetamol) in patients with COVID-19.
There was no specific data referenced to support
his recommendation.6 His comments appear to
have resulted from media reports of four cases of
younger patients in France with COVID-19 who
took ibuprofen for their symptoms and went on
to have worsening symptoms.7 No demographic
or descriptive information about these patients
has been published, and the timing and dosing of
ibuprofen in relation to their COVID-19 symptoms
are not known.
Following this, several health and governmental
groups issued commentary on this subject. The
WHO initially recommended that ibuprofen use
should be avoided for symptoms of COVID-19.
They then reversed that recommendation on 18
March 2020 stating, ‘based on currently available
information, WHO does not recommend against the
use of ibuprofen’.8 The European Medical Agency,
also on 18 March 2020, stated, ‘there is currently
no scientific evidence establishing a link between
ibuprofen and worsening of COVID-19’.9 This
organization did comment that there is evidence
that NSAIDs could contribute to a more severe
course of chickenpox and some bacterial infections.
It also suggested that acetaminophen (paracetamol)
was generally the preferred agent for fever and pain
during an infectious illness and called for further
research on the impact of NSAID use in patients
with COVID-19. On 19 March 2020, the US Food
and Drug Administration issued a statement that
it was ‘not aware of scientific evidence connecting
the use of NSAIDs, like ibuprofen, with worsening
COVID-19 symptoms’.10 On 19 April 2020, the
WHO released a scientific brief to address NSAID
use in patients with COVID-19.11 While they note
the limitation of a current lack of studies directly
examining NSAID use in patients with COVID-19,
their review included 73 relevant published studies.
After examining these studies, the WHO found no
evidence to suggest that NSAID use in patients with
COVID-19 results in significant adverse events or
increased mortality.
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An article examining the impact of NSAID use in patients with
COVID-19 noted that while there is evidence that NSAIDs can
worsen outcomes in patients with respiratory infections, there is
no strong signal yet detected to show this occurs in patients with
COVID-19. However, the author notes that there are potential
risks associated with using NSAIDs in patients without infection
including heart attacks, stroke and kidney injury. The author
suggests these risks could be increased if fever and dehydration
occur due to an infection like COVID-19. Given the potential
risks, the author concluded that NSAIDs should likely not be
first-line treatment for fever and pain in patients with COVID19.12 However, a recent review article that also examines potential connections between NSAIDs and COVID-19 noted that
studies examining ibuprofen’s connection with the outcomes
of respiratory illnesses are often at risk of different types of
biases.13 Potential biases include the risk of assuming a causality
between ibuprofen administration and a disease’s natural course
of severity when they may not be related (protopathic bias)
and also the risk of selection bias where NSAIDs may not be
used unless more severe symptoms are present. Additionally,
many patients who take NSAIDs chronically for pain have other
chronic medical conditions that can increase their risk profile for
poorer COVID-19 outcomes compared with otherwise healthy
patients—making attempts to correlate NSAID use with respiratory illness outcomes a challenging endeavor. It should be noted
that many studies examining NSAIDs and respiratory infection
outcomes focus on bacterial rather than viral illnesses. One retrospective study from 2016 examined NSAID use in H1N1 influenza patients and found ‘no compelling evidence’ that NSAID
use increased mortality in these patients.14 Interestingly, a recent
prospective trial of hospitalized patients with influenza found
that the use of naproxen, in conjunction with other medications,
actually yielded a mortality benefit.15

Conclusion

While an absence of evidence regarding NSAIDs interplay with
the manifestation of COVID-19 symptoms and subsequent
severity of illness does not necessarily equate to evidence of
absence, the current state of the data surrounding this claim
must be considered when currently treating patients. At present,
we cannot locate any data showing that ibuprofen worsens
the severity of COVID-19 symptoms or increases one’s likelihood of contracting the illness. Similarly, in a recent article
by a fellow pain medicine physician in Italy, no link between
NSAIDs and COVID-19 could be found in the published literature.16 Furthermore, the present concerns that have been raised
regarding NSAIDs have been specific for their use in patients
with COVID-19 symptoms, not asymptomatic patients who
otherwise have pain that needs to be treated.
At this time, there is no reason to remove NSAIDs as an option
for treating appropriate patients in pain, especially if they are
without possible or confirmed COVID-19 symptoms. The presence of a pandemic does not alter the baseline risks of NSAIDs
use, which should be avoided or used with caution in several
situations including when treating patients who have renal or
cardiovascular disease or advanced age. That said, no pharmacologic treatment for pain is without risks, and other options have
been associated with worsening immune function. For example,
the role of opioids functioning as an immunosuppressant have
been well documented.17–19 Thus, it appears reasonable for
patients who take NSAIDs chronically to continue to do so and
to continue to use this class of medication judiciously to treat
acute pain as well. However, until more data arises, it would be
678

reasonable, out of an abundance of caution, to avoid NSAID use
in patients who have possible symptoms of, or recent high-risk
exposures to, COVID-19.
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